SAN DIEGO — Following a talk by Leigh Anderson that showed that the number of new protein-based diagnostic tests that have been approved by the US Food and Drug Administration has declined over the last 10 or so years, scientists here at the Cambridge Healthtech Institute's PEPTALK conference discussed why proteomics has not yet produced a biomarker that has made a significant clinical impact.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.